Melbourne, June 28, 2026, 23:06 AEST
- CSL ended Friday at A$114.87, slipping 2.36% for the day and off 1.2% over the week.
- The stock’s A$7.99 range for the week adds up to around A$3.8 billion across 478.91 million shares.
- The EU opened an antitrust probe into Sanofi’s flu vaccine push involving CSL Seqirus’ Fluad, Reuters said. News came after the ASX closed. EMA, separately, advised pulling Tavneos’ EU approval.
- CSL closes its fiscal year on June 30. The company plans to release its full-year results and declare its final dividend on Aug. 18.
CSL Limited ASX:CSL heads into this week after shares ended at A$114.87 on Friday, dropping 2.36%. The session saw ASX normal cash trading run from about 09:59:45 to 16:00 Sydney time.
CSL slipped 1.2% for the week, measured from the June 19 close. Trading stayed volatile: the stock dropped to A$110.89 on Monday, then jumped to A$118.88 by Thursday. With 478.91 million shares out, that’s an A$7.99 trading band, or about A$3.8 billion in market cap.
Trading volume was high, with 10.5 million CSL shares moving over five sessions, about 2.1 million a day. That’s above the three-month daily average of 1.91 million. The S&P/ASX 200 lost 0.7% for the week. CSL trailed the main index by roughly 0.5 point.
Timing is the story Monday after Reuters said at 09:46 UTC Friday that the European Commission is looking into Sanofi SA EPA:SAN over possible violations of EU competition law tied to a flu vaccine campaign. According to the report, the Commission has concerns Sanofi pushed Efluelda with a misleading campaign while criticizing CSL Seqirus’s Fluad in France and Germany.
ASX cash trading was already closed for the week when that report came out. CSL had not issued any announcement about how the probe might hit its finances. For shareholders, the real focus is on the business line: Reuters in April said CSL Seqirus pulled in about $2.17 billion of fiscal 2025 revenue, close to 14% of the company total.
Flu has been dragging on the stock. Marc Jocum, senior product and investment strategist at GlobalXETFs, told Reuters in April that CSL faces pressure from weaker U.S. flu vaccination rates, soft Seqirus earnings, and delayed strategic plans.
Another move from Europe heads in the other direction. The European Medicines Agency said its human medicines committee wants EU marketing authorisation for Tavneos pulled, saying the benefits aren’t proven to outweigh the risks anymore. EMA said the main study’s data can’t be relied on for effectiveness and told doctors to keep new patients off the drug.
CSL said it sells Tavneos outside the US in select countries through CSL, its affiliates and partners. Bill Mezzanotte, CSL’s head of research and development, said the company’s top focus is “patient care” and CSL will coordinate with regulators and doctors to manage treatment changes. Global Newsroom | CSL
CSL reset its outlook in May, after management warned on timing. Interim CEO Gordon Naylor said CSL’s growth push is underway, though “financial benefits will take longer.” The company is now guiding for about $15.2 billion in revenue and about $3.1 billion NPATA for fiscal 2026, both on a constant-currency basis, adjusted for restructuring and impairments.
CSL broke out the guidance cut. The company said its U.S. immunoglobulin revenue would take a hit of about $300 million. For albumin in China, the impact is around $200 million. Other impacts, including slower HEMGENIX growth and iron market pressure, came to about $150 million.
CSL heads into its fiscal year-end on Tuesday, but there’s no earnings release set for the week. The company’s financial calendar puts its full-year results and final dividend call on Aug. 18. Last month, CSL said in an update that the Seqirus operational separation is still planned for July 1.
CSL finished Friday up 27.6% from its intraday low of A$90 on June 3. The stock is still off 51.0% for the past year.
